HUTCHMED Cancer Med Cuts Death Risk By 34% In Metastatic Colorectal Cancer

• HUTCHMED (China) Limited (NASDAQ: HCM) announced summary results of the 691-patient trial of fruquintinib. These results have been shared in an abstract of the upcoming presentation at the European Society for Medical Oncology Congress 2022.

• The MRCT FRESCO-2 study demonstrated that treatment with fruquintinib resulted in a statistically significant and clinically meaningful increase in the primary overall survival (OS) endpoint and key secondary progression-free survival (PFS) endpoint compared to treatment with placebo.

• The median OS was 7.4 months for the 461 patients treated with fruquintinib compared to 4.8 months for the 230 patients in the placebo group.

• Median PFS was 3.7 months for patients treated with fruquintinib compared to 1.8 months for patients in the placebo group.

• The disease control rate was 55.5% in the fruquintinib group compared to 16.1% for patients in the placebo group.

• The safety profile of fruquintinib in FRESCO-2 was consistent with previously reported fruquintinib studies.

• Price Action: HCM shares are trading 4.74% higher at 13.03 on the last check Thursday.

See more from Benzinga

• A Biotech's Stock Just Hit Year High. This Analyst Expects It To Jump Another 16%

• Gilead's Trodelvy Shows Improved Overall Survival In Pretreated Breast Cancer Settings

• GameStop (NYSE:GME) – Apes Have Locked Up This Many Million GameStop Shares On DRS: What's Going On?

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.